SAN DIEGO--(BUSINESS WIRE)--Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced the launch of its ...
NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx). Background: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results